Beamtree Holdings Ltd · ASX:BMT
Beamtree — H1 FY2022 Earnings Presentation
26 slides from Beamtree's earnings presentation, March 2022
Slide 1: Half Year Investor Presentation
personal use only Half Year Investor Presentation March 2022
Slide 2: Financial Summary 1H FY22
Financial Summary 1H FY22 Growth and investment was the focus for the first half of FY22, despite ongoing challenges presented by the personal use only COVID-19 pandemic. Thanks to strong revenue performance and excellent customer retention rates, we were able to make significant investments across
Slide 3: Beamtree has seen continued growth in the first half of FY22
Beamtree has seen continued growth in the first half of FY22 personal use only Key acquisition of Potential(x) making Beamtree Australia’s largest health data and AI decision support platform. Ai Key acquisition of Ainsoff to drive AI product innovation. 100% of our retention and renewal goals for t
Slide 4: Building our international program – snapshot of progress
Building our international program – snapshot of progress New contract wins in four countries. Groundbreaking strategic partnerships to develop new applications in computer-assisted clinical record coding and remote monitoring of patient deterioration personal use only • Central Adelaide LHN has bec
Slide 5: Our growth strategy is based on global acceleration in five product and service domains
Our growth strategy is based on global acceleration in five product and service domains personal use only Diagnostic technology We enable the efficient and effective delivery of the diagnostic services as they underpin the future of heath and personalised medicine. Automation, coding and data integr
Slide 6: The propositions have attractive fundamentals total market size of ~$120b in 2026/27
The propositions have attractive fundamentals total market size of ~$120b in 2026/27 STRATEGIC OVERALL personal use only SCALE & GROWTH ACHIEVABILITY COMPETITION / ENTRY ALIGNMENT ASSESSMENT DIAGNOSTIC TECHNOLOGY • Est 10% CAGR, ~$2.9b to 2027 (Diagnostic Support) • High: especially through sound Ch
Slide 7: The problems we solve
the problems we solve The best health services deliver value for money by reducing avoidable mortality, waste, length of stay, personal use only readmissions and cost of care. Complications are costly. One in nine patients who go to hospital suffer a complication, which costs Australian hospitals mo
Slide 8: How we create value: the Learning Health System
How we create value: the Learning Health System Driving continuous improvement by better access to healthcare information – towards safety, quality and efficiency. personal use only Return knowledge to Collect health the rules engine information Support clinicians Encode in standard coders and forma
Slide 9: Data, insights and action for better healthcare
Data, insights and action for better healthcare Our solutions and services help clients make the best use of their data. From improving the quality of the inputs, personal use only to better visualising the outputs and automating decisions, we help healthcare providers make informed decisions and im
Slide 10: Beamtree is creating next-generation solutions to enable the Clinical and Informatics Users
Beamtree is creating next-generation solutions to enable the personal use only Clinical and Informatics Users • RippleDown® Decision Support • Automating safety alerts • Practice Analytics Organisation • Automated Coding • Organisational Performance & Predictive Analytics • Management Reporting • Al
Slide 11: Highlights of FY22
Highlights of FY22 personal use only Copyright © Beamtree Holdings Limited – All Rights Reserved 11
Slide 12: Media Mentions
Media Mentions personal use only "The beauty of the system is when you look at the New hospital system predicts the future of a patient's condition Oct 28, 2021 single ward say 30 https://www.9news.com.au/national/new-medical-system-for-hospitals-monitor- patients-warning-signs-new-south-wales/e1b8e
Slide 13: Key Partnerships and International Expansion
Key Partnerships and International Expansion personal use only • Strategic partnership with Central Adelaide Local Health Network (CALHN) in South Australia to implement its decision support platform. • A strategic partnership with Southern DHB in New Zealand to implement proprietary data capture ba
Slide 14: Collaborative Partnerships
Collaborative Partnerships As part of the acquisition of Potential(x), Beamtree now provides services to the following organisations. personal use only • Established in 2013, Ability Roundtable is a not-for-profit benchmarking and knowledge-sharing organisation in the disability sector. • Continued
Slide 15: New Products & Enhancements
New Products & Enhancements Growth in microbiology and pathology personal use only RippleDown® Artificial Intelligence (AI) decision support expanded into microbiology and pathology services in several new countries with channel partners Philips and Abbott. Improvements and enhancements Major new re
Slide 16: Thought Leadership & Collaboratives
Thought Leadership & Collaboratives Global Impact Committee personal use only Chaired by Mark Britnell, this advisory board includes 15 international healthcare leaders from Australia, Canada, UK, Ireland, USA, Singapore, India, Italy and Sweden. Following the first meeting in October, the committee
Slide 17: Beamtree and Potential(x) Integration Rationale
Beamtree and Potential(x) Integration Rationale personal use only Accelerate growth in new global markets and adjacent sectors Add value and market access for existing solutions and software Reduce barriers to entry in ANZ market Immediate market share, expertise and insight into public hospital sec
Slide 18: Beamtree and Potential(x) Integration Update
Beamtree and Potential(x) Integration Update personal use only To identify and action efficiencies in the organisational ways of working, value-creation, cost containment and avoidance, and organisation and operational alignment. The first 100 days of the PMI finished on track with nearly 60% of the
Slide 19: New Executive Team
New Executive Team personal use only Tim Kelsey Cheryl McCullagh Chief Executive Officer Chief Strategy Officer (Global) Duane Attree Cassandra Chen Chief Commercial and Development Officer Chief Financial Officer – Outgoing Mark McLellan Chief Financial Officer – Incoming
Slide 20: Financial Summary 1H FY22
personal use only Financial Summary 1H FY22
Slide 21: 1H FY22 – continued strong revenue growth
1H FY22 – continued strong revenue growth Comments personal use only $(,000) 1H FY22 1H FY21 YoY Var $ YoYVar% • Total Revenue growth of 91%, up to $7.1m supported by 23.5% organic revenue growth YoY (exc. Acquisitions) due to Subscription, License & Usage new contract wins and strong performance in
Slide 22: Revenue Composition
Revenue Composition 1H FY22 % of Recurring Revenue Revenue Profile personal use only 15% 15% 3% $7.1m $7.1m 50% Revenue Revenue 32% 85% Subscription, License & Usage - recurring Recurring Non-recurring Data Analytics - recurring Coding Service - recurring Consultancy & Initial license fee Revenue Co
Slide 23: Annual Recurring Revenue Growth
Annual Recurring Revenue Growth Comments personal use only • Annual Recurring Revenue (ARR) has increased at a CAGR of 72% since 1H FY20 on statutory basis. $,000 • The acquisition of Potential(x) has substantially increased Beamtree’s ARR through data analytics by adding $9.2m as 16,814 at the half
Slide 24: Statutory Balance Sheet
Statutory Balance Sheet Comments personal use only $(,000) 31 Dec 2021 30 June 2021 • $6.5m of net cash – position remains strong Assets • Debtors balance increased by $3.1m compared to 30 June Current assets 2021. Debtor balance of Potential(x) contributes $1.8m to the total of which $1.6m related
Slide 25: Statutory Cashflow
Statutory Cashflow Comments personal use only $(,000) 1H FY22 Operating cashflow Receipts from customers (inclusive of GST) 6,644 • Net cash outflow is driven by timing in receiving $1.9m (USD Payments to suppliers and employees (inclusive of GST) (8,866) $1.4m) from completion of Saudi project (exp
Slide 26: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 15 personal use only February 2022. This presentation may contain statements that are, or may be deemed to be,